Why This Beaten-Down Stock's Growth Story Is Far from Over
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.
If you're a Vertex Pharmaceuticals (NASDAQ: VRTX) shareholder, you're surely not too happy about the stock's recent performance. The biotech giant discontinued development of VX-814, a candidate for alpha-1 antitrypsin deficiency (AATD, an inherited condition that can increase risk for lung or liver disease), and the stock sank 20% in one trading session in the middle of October.
The losses didn't end there; Vertex shares continued to slip, posting a 24% total decline for October. They are now at about the same level they reached during the March market crash. At the same time, sales and net income in the most recent quarter soared, and the company raised annual revenue guidance. It's clear that -- regardless of short-term share performance -- Vertex's growth story can fill many pages well into the future. Let's take a closer look.
Source Fool.com
